Trump Declares Heavy Tariffs: Pharmaceutical Industry May Fully Localize
On Tuesday, U.S. President Trump stated that the U.S. government would soon announce a new round of tariffs on key imports such as pharmaceuticals and semiconductors. Of notable interest, he clearly stated for the first time that pharmaceutical tariffs would gradually rise from a lower level to 150%, and could eventually reach as high as 250%.
This aggressive tariff strategy marks another significant move by the Trump administration in reshaping global trade structures. Behind it, there is not only pressure on pharmaceutical manufacturing giants like China and India but also a strategic vision to "forcibly" achieve the repatriation of pharmaceutical production to the U.S.
"We want the drugs to be manufactured domestically," Trump stated bluntly in an interview with CNBC. He emphasized that pharmaceuticals are a crucial part of national security, and excessive reliance on overseas supplies is an unacceptable risk.
Global Pharmaceutical Supply Chain Faces Major Shakeup
The U.S. is one of the world's largest importers of pharmaceuticals, especially relying heavily on foreign sources for generic drugs and active pharmaceutical ingredients (APIs). According to FDA data, nearly 80% of APIs in the U.S. come from abroad, mainly from India and China.
Once the pharmaceutical tariff policy is officially implemented, it is expected to trigger a chain reaction in the global pharmaceutical manufacturing industry. Chinese generic drug manufacturers, Indian API suppliers, and global multinational pharmaceutical companies will need to reassess their export models and cost structures to the U.S.
The International Association of Pharmaceutical Manufacturers warned in a confidential memo that if the U.S. proceeds with extreme tariff measures, it would cause "systemic disruption" to the global pharmaceutical supply chain, potentially leading to short-term drug price increases and deterioration of long-term partnerships.
Parallel Pressure on Semiconductors and Pharmaceuticals
In addition to pharmaceuticals, Trump also mentioned upcoming restrictions on semiconductor and chip imports. This aligns with last year's "Critical Technology Supply Chain Rebuilding Plan," continuing the administration's high-pressure stance on technological security and autonomy.
Trump did not specify the exact semiconductor tariff rates, but the market generally anticipates that the policy will focus on mid- to low-end chips, while further intensifying constraints on countries deeply reliant on advanced processes.
Targeting both pharmaceuticals and chips in this policy marks the Trump administration's strong motivation for "de-globalization" in key industries, attempting to combine national strategic security with manufacturing revival to further consolidate voter support for economic nationalism.
Market Reactions and Political Motives Intertwine
Following Trump's tariff remarks, all three major U.S. stock indexes fell, with the pharmaceutical and technology sectors noticeably under pressure. The Dow Jones dropped nearly 62 points, while the Nasdaq fell more than 130 points.
Analysts pointed out that although Trump's announcement has not yet been officially documented, the expected management effect is already evident. It heightens corporate concerns about policy risks on one hand, and on the other, it may serve to strengthen his narrative on economic sovereignty ahead of the election.
It should be noted that Trump's recent emphasis on external economic pressure and expanding trade barriers is seen as an effort to gain more grassroots support for his "economic populism," particularly in the "Rust Belt" and southern states.
Global Countermeasures and Supply Substitution
As the U.S. potentially implements significant pharmaceutical tariffs, how key pharmaceutical exporting countries respond becomes the next point of focus. The EU has called on the World Trade Organization to review the legalities, while India's Health Minister recently stated that they would closely evaluate their export strategies and policy adjustments.
Simultaneously, if U.S. pharmaceutical companies cannot quickly establish a stable supply chain due to rising costs, they may be forced to promote supply models such as "Latin American substitution" or "Southeast Asian shift." This implies that the global pharmaceutical geopolitical landscape may undergo structural changes due to Trump's actions.
It is foreseeable that if this tariff escalation is implemented, it will not only be an economic policy but also another reinforcement of Trump's "Made in America" commitment. The consequences will extend far beyond the fluctuation in drug prices, potentially reshaping the entire global pharmaceutical ecosystem.
